Alnylam Pharmaceuticals Reaches Analyst Target Price
May 17, 2017 at 09:00 AM EDT
In recent trading, shares of Alnylam Pharmaceuticals Inc (ALNY) have crossed above the average analyst 12-month target price of $70.69, changing hands for $72.01/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..